[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cantonal Hospital of St. Gallen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":222},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,78,111,137,170,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643157","flow-controlled-ventilation-to-improve-postoperative-pulmonary-outcome-after-thoracic-surgery-100643157",false,"NCT07623395","Flow-Controlled Ventilation to Improve Postoperative Pulmonary Outcome After Thoracic Surgery","PROtective Ventilation With FLOW-Controlled Ventilation to Improve Postoperative Pulmonary Outcome After THORACic Surgery - an International Multicenter Pilot Randomized Clinical Trial","PROFLOW-THORAC","Inclusion Criteria:\n\n* aged ≥ 18 years; and\n* scheduled for elective open, video- or robot-assisted thoracic surgery with one-lung ventilation using a double-lumen tube (DLT); and\n* able to give written informed consent.\n\nExclusion Criteria:\n\n* body weight \\\u003C 40 kg;\n* ASA score IV - VI;\n* lung separation with other method than DLT (e.g. difficult airway, tracheostomy);\n* previous lung surgery;\n* COPD GOLD grades III and IV, lung fibrosis, documented bullae, severe emphysema, pneumothorax;\n* uncontrolled asthma;\n* Heart failure NYHA Grade 3 and 4, Coronary Heart Disease CCS Grade 3 and 4;\n* documented pulmonary arterial hypertension \\>25 mmHg mPAP at rest or \\>40mmHg syst. (estimated by ultrasound) or \\>20 mmHg mPAP measured by right heart catheterization, or pulmonary vascular resistance \\> 2.0 Wood units;\n* documented or suspected neuromuscular disease (thymoma, myasthenia, myopathies, muscular dystrophies, others);\n* planned mechanical ventilation after surgery;\n* bilateral procedures;\n* surgery in prone position;\n* persistent hemodynamic instability, intractable shock;\n* intracranial injury or tumor;\n* esophagectomy, pleural surgery only, sympathectomy surgery only, chest wall surgery only, mediastinal surgery only, lung transplantation;\n* presence before induction of anesthesia of one of the adverse events, listed as postoperative pulmonary complications (aspiration, moderate respiratory failure, infiltrates, pulmonary infection, atelectasis, cardiopulmonary oedema, pleural effusion, pneumothorax, pulmonary embolism, purulent pleuritis, lung hemorrhage);\n* documented preoperative hypercapnia \\> 45mmHg (6kPa)\n* previous enrolment in the current study;\n* being the study investigator of this study, his\u002Fher family members, employees and other dependent persons;\n* if female and of childbearing potential, known pregnancy or a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating; or\n* no written informed consent.","ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","In an international multicenter randomized clinical pilot trial, intraoperative flow-controlled ventilation (FCV) will be compared with volume-controlled ventilation (VCV) in patients scheduled for (open, video- or robot-assisted) thoracic surgery with one-lung ventilation (OLV). This pilot trial is designed to test the feasibility and safety of FCV during all phases of intraoperative ventilation, and in particular during OLV, and to inform the design of a future trial testing the efficacy of FCV with regard to postoperative outcomes, including postoperative pulmonary complications (PPC).\n\nThe ventilation modes are conducted with CE-marked medical devices (anesthesia ventilators or medical ventilators), however these medical devices themselves are not under investigation. All CE-marked standard medical devices from varied manufacturers in use at the participating study centers will be used in full accordance with their instructions for use. FCV has shown safety and feasibility in various surgical settings, including thoracic surgery with OLV, however its feasibility in a multicenter trial has not been investigated yet.",[27,28],"Mechanical Ventilation","Postoperative Pulmonary Complications (PPCs)",[30,31,32,33],"Flow-Controlled Ventilation","Thoracic Surgery","One-Lung Ventilation","Mechanical Power","NOT_YET_RECRUITING","2026-06-28",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":21},"2026-09-01",{"date":42,"type":21},"2027-12-01",{"name":44,"class":45},"Cantonal Hospital of St. Gallen","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100570174","protective-ventilation-with-flow-controlled-ventilation-100570174","NCT06703814","PROtective Ventilation With FLOW-Controlled Ventilation","PROtective Ventilation With FLOW-Controlled Ventilation to Improve Postoperative Pulmonary Outcome After ROBOT-Assisted Laparoscopic Surgery - an International Multicenter Pilot Randomized Clinical Trial.","PROFLOW","Inclusion Criteria:\n\n* undergoing elective robot-assisted laparoscopic surgery in supine or Trendelenburg position (either abdominal, urologic or gynecologic surgery);\n* AND increased risk of PPCs according to the ARISCAT risk score (≥ 26 points);\n* OR the combination of age \\> 40 years, scheduled surgery lasting \\> 2 hours and planned to receive an intra-arterial catheter for blood pressure monitoring during the surgery;\n* aged ≥ 18 years; and\n* able to give written informed consent to participate in the study and agree to comply with the study protocol prior to initiation of any study-mandated procedure and study intervention.\n\nExclusion Criteria:\n\n* ideal body weight \\\u003C 40 kg;\n* ASA Physical Status Classification System score IV - VI;\n* previous enrolment into the current study;\n* being the study investigator, his\u002Fher family members, employees and other dependent persons;\n* if female and of childbearing potential, known pregnancy or a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating; or\n* No informed consent",true,{"count":57,"type":21},100,[24],"The investigators want to investigate in patients undergoing robot-assisted laparoscopic surgery (a minimally invasive procedure) how applicable flow-controlled ventilation is, and whether it might also be safer than the current ventilation techniques, as well as its impact on potentially reducing the risk of lung-specific complications.\n\nFlow-controlled ventilation has already been tested in several studies on animals and humans and has proven to be a safe form of ventilation for patients undergoing surgery under general anesthesia.\n\nWhen patients undergo major surgery, general anesthesia is required and, as a result, mechanical ventilation of the lungs. Especially in long and complex surgeries, ventilation can become more difficult or lead to complications postoperatively. These patients may then experience shortness of breath, coughing, or require medication to improve lung function. In some cases, reintubation or additional mechanical ventilation may be necessary for support.\n\nPrevious human studies have shown that flow-controlled ventilation is less stressful and, therefore, potentially safer for the lungs compared to traditional ventilation techniques, and that less supplemental oxygen is required. This effect and the safety of flow-controlled ventilation have been demonstrated in several studies.\n\nTherefore, in this study, the investigators aim to explore whether flow-controlled ventilation is potentially safer and easier to apply than traditional ventilation techniques and whether it can reduce the risk of lung-specific complications following robot-assisted surgeries, thereby improving the recovery process postoperatively.",[28,61,62],"Feasibility Studies","Pilot Study",[64,65,66,67],"flow-controlled ventilation","postoperative pulmonary complications","mechanical ventilation","intraoperative ventilation","RECRUITING","2026-04-16",{"date":71,"type":38},"2026-04-21",{"date":73,"type":38},"2025-08-02",{"date":75,"type":21},"2026-05-31",{"name":44,"class":45},3,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":46},"100543195","determining-postoperative-recovery-and-the-impact-of-adverse-events-in-neurosurgery-based-on-self-reported-app-based-longitudinal-assessment-100543195","NCT06352710","Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment","Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment - a Collaborative Observational Research Project","Inclusion Criteria:\n\n* Age ≥ 18 years\n* The patient must be able to consent\n* The patient is willing to provide data upon one year after surgery\n* The patient possesses and is capable of using a smartphone (Android or iOS operative systems)\n* The patient has the necessary language and cognitive skills to use the smartphone app\n* The patient is scheduled for one of the defined operations (see above for both spinal and cranial) and in a stable, non-life-threatening situation (admitted to the regular ward or intermediate care unit (IMC))\n* Baseline preoperative SWI and QoL assessment is possible (minimum requirement is one assessment, the latest the day before surgery)\n\nExclusion Criteria:\n\n* Pregnancy\n* Foreseeable difficulties using the smartphone or smartphone app\n* The presence of a condition that hinders the baseline preoperative assessment\n* Health conditions that render inclusion unsafe (e.g., untreated ruptured intracranial aneurysm or congestive heart failure; in general, all patients admitted to the intensive care unit (ICU))",{"count":86,"type":21},400,"OBSERVATIONAL","Analyzing the impact of surgery and adverse events (AEs) on patients' well-being is of paramount importance as it provides essential information for benefit-risk assessment. Current methods in outcome research are static, resource-intensive and subject to missing-data issues. Moreover, AEs are inconsistently reported using various grading systems that usually do not account for patients' subjective well-being. These are severe drawbacks for outcome research as it hinders monitoring, comparison, and improvement of treatment quality.\n\nThe increasing use of smartphones offers unprecedented opportunities for data collection. The investigators developed a free smartphone application to assess fluctuations of patients' well-being as a result of surgical treatment and possible AEs. The application is installed on each patient's smartphone and collects standardized data at defined timepoints before and after surgery (well-being, AE description and severity).\n\nBy acquiring longitudinal patient-reported outcome before and after neurosurgical interventions, the investigators aim to determine the regular postoperative course for specific surgical procedures, as well as any deviation thereof, depending on the occurrence and severity of AEs. The investigators will evaluate the validity of existing AE classifications and, if necessary, propose a new patient-centered scheme. The investigators hope that this will result in an increase in standardized reporting of patient outcome, and ultimately allow for evidence-based patient information and decision-making.",[90,91,92,93],"Disc Disease","Instabilities Lumbar","Brain Tumor","Aneurysm",[95,96,97,98,99,100,101,102],"Outcome","PROMs","App","Neurosurgery","Adverse event","Complication","Quality of life","TDN","2026-03-17",{"date":105,"type":38},"2026-03-19",{"date":107,"type":38},"2023-06-12",{"date":109,"type":21},"2027-12-31",{"name":44,"class":45},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":136},"100630087","fiber-boost-randomized-controlled-trial-100630087","NCT07483112","Fiber-Boost Randomized Controlled Trial","Multicenter, Randomized, Controlled Trial to Study the Effects of a High-Fiber Dietary Intervention on ctDNA Clearance and the Microbial and Immunological Landscape in Patients With Advanced Non-Small Cell Lung Cancer Receiving PD-1\u002FPD-L1-Targeted Monotherapy (Fiber-Boost)","Fiber-Boost","Inclusion Criteria:\n\n* Age ≥18 years\n* Written informed consent according to Swiss law and ICH\u002FGCP regulations before inclusion and prior to any trial-specific procedures\n* Histologically or cytologically confirmed NSCLC\n* Advanced or recurrent NSCLC not amenable to curative treatment\n* PD-L1 expression ≥50% (TPS) determined by an approved IHC test\n* No actionable genetic alterations in genes such as EGFR, ALK, ROS1, HER2, BRAF, RET, MET, NTRK\n* First-line palliative PD-1\u002FPD-L1-targeted monotherapy at a 3-weekly schedule indicated per local investigator\n* Willingness and ability to undergo study interventions\n* ECOG performance status 0-2\n* Adequate organ function:\n* Hemoglobin ≥70 g\u002FL, platelet count ≥50 G\u002FL, granulocytes ≥1 G\u002FL\n* Bilirubin, ALT, AST ≤3 x ULN\n* Glomerular filtration rate (Cockroft-Gault) ≥30 mL\u002Fmin\u002F1.73m²\n* Measurable or evaluable disease per RECIST 1.1\n* Patients with CNS metastases are eligible, provided there is no requirement for corticosteroids as therapy for CNS disease and no evidence of clinical progression\n* Women with child-bearing potential use effective contraception (two independent methods), are not currently pregnant or lactating, and agree to not become pregnant during the trial treatment and during 3 months thereafter. A negative pregnancy test in either urine or blood is required for women with child-bearing potential before trial inclusion.\n* Men who are not sterile agree to use contraceptive methods (condoms) or abstain from sexual intercourse during the trial treatment and 3 months thereafter.\n\nExclusion Criteria:\n\n-History of malignancy, unless in remission for at least 3 years before inclusion with the exception of pT1-2 prostate cancer Gleason score \\\u003C6, adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer\n\nAdjuvant or additive systemic ICB treatment within 6 months prior to inclusion\n\n* Systemic treatment with an antibiotic within 10 days of ICB treatment\u002FHFD intervention start\n* Concomitant immunosuppressive drugs including corticosteroids at a daily dose of ≥10mg prednisone equivalents, methotrexate, azathioprine, TNF-α inhibitors\n* Concurrent treatment with other experimental drugs or other anticancer therapy\n* Major surgical procedures within 14 days prior to inclusion as judged by the investigator\n* Active autoimmune disease requiring systemic immunosuppressive treatment that is seen as contraindication for the use of PD-1\u002FPD-L1-targeted monoclonal antibodies\n* Uncontrolled diabetes mellitus\n* Severe or uncontrolled cardiovascular disease\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications\n* Had an allogeneic tissue\u002Fsolid organ transplant\n* Ongoing supplementation with OptiFibre® or another fiber supplement",{"count":120,"type":21},42,[24],"In the present study 'Fiber-Boost', we investigate how a high-fiber diet affects the immunotherapy of advanced lung cancer and what effects it has on the gut microbiome (i.e., the bacteria in the gut) as well as the immune system. Study participants will be assigned to either a test group or a control group. Only patients in the test group will undergo a high-fiber diet. The study lasts 6 weeks per patient and will be conducted at 4 centers within Switzerland. A total of 42 patients are planned to be included in the study.",[124],"Non-Small Cell Carcinoma of Lung",[126,127,128,129],"non-small cell lung cancer","immunotherapy","high-fiber diet","microbiome","2026-03-16",{"date":105,"type":38},{"date":133,"type":38},"2025-10-07",{"date":109,"type":21},{"name":44,"class":45},4,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":55,"sex":17,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":157,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":46},"100537528","phase-3-colchicine-in-patients-at-cardiac-risk-undergoing-major-non-cardiac-surgery-100537528","NCT06279000","Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery","Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery: Prospective, Randomized, Double-blinded, Placebo-controlled, Multi-centre Study","COLCAT","Inclusion Criteria:\n\nundergoing major non-cardiac surgery in general anaesthesia will be included. Major non-cardiac surgery is defined as:\n\n* vascular surgery (with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies)\n* intraperitoneal surgery\n* intrathoracic surgery\n* major orthopaedic surgery (spinal surgery or joint replacement surgery)\n* at cardiovascular risk, defined as meeting at least 1 of the following 6 criteria:\n\n  * preoperative n-terminal pro brain natriuretic peptide (NT-proBNP) ≥ 200 ng\u002Fl\n  * history of coronary artery disease\n  * history of peripheral vascular disease\n  * history of stroke\n  * undergoing major vascular surgery, with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies\n  * fulfilment of any 3 of the 8 following criteria:\n\n    * undergoing major surgery (intrathoracic, intraperitoneal or supra-inguinal vascular surgery)\n    * any history of congestive heart failure or history of pulmonary oedema\n    * anamnestic transient ischemic attack (TIA)\n    * diabetes under treatment with either oral antidiabetic agent or insulin\n    * age \\> 70 years\n    * history of hypertension\n    * serum creatinine \\> 175 mumol\u002Fl or calculated creatinine clearance \\< 60 ml\u002Fmin\u002F1.73m2 (cockcroft gault)\n    * history of smoking within 2 years of surgery\n    * planned surgical time ≥ 90 minutes\n    * planned postoperative hospital stay at least 1 night\n\nExclusion Criteria:\n\n* no written consent\n* inclusion in other clinical trial with direct impact on perioperative medication\n* previously reported side effects or reported intolerance from colchicine (e.g., allergic reaction or significant sensitivity to colchicine or an auxiliary substance of the IMP)\n* pregnancy or planned pregnancy and\u002For breast feeding\n* clinically significant history of drug or alcohol abuse within the last year\n* very severe frailty (≥ 8 clinical frailty scale)\n* patient with inflammatory bowel disease (e.g., Morbus Crohn or Colitis ulcerosa)\n* patient taking colchicine for other indications (e.g., familial Mediterranean fever, gout)\n* severe renal impairment (eGFR \\< 30 ml min -1 1.73 m2 -1) or end-stage renal disease with indication for haemodialysis\n* history of solid organ or bone marrow transplantation\n* systemic immune-suppression (medication (steroids \\>30mg cortisol-equivalent per day, tacrolimus etc...) or disease (e.g., myelodysplastic syndrome)\n* severe hepatic impairment with history of cirrhosis\n* chronic active hepatitis or functional disorders defined as alanine aminotransferase greater than three times the upper limit of normal\n* anticipated post-operative administration of CYP3A4 metabolized substances like cyclosporine, ketoconazole, clarithromycin, verapamil, quinidine, diltiazem or ritonavir\n* Any other condition that the investigator would consider a risk to the patient if the latter were to participate in the study.","45 Years",{"count":147,"type":21},880,[149],"PHASE3","Perioperative myocardial injury and major adverse cardiovascular events (MACE) are common causes of morbidity and mortality in patients at increased cardiovascular risk undergoing non-cardiac surgery.\n\nHowever, research in recent years has yielded limited preventive and therapeutic measures for myocardial injury\u002FMACE. Recent studies in patients with chronic and acute coronary artery disease have shown that colchicine administration can reduce the risk of cardiovascular events.\n\nThese encouraging results in non-surgical patients ask for a similar investigation in patients undergoing major non-cardiac surgery. The aim of the proposed study is to investigate the effects of perioperative colchicine administration on the incidence of myocardial injury\u002FMACE.",[152,153,154,155,156],"Cardiovascular Diseases","Cardiovascular Complication","Perioperative Complication","Myocardial Injury","Myocardial Injury After Noncardiac Surgery (MINS)",[158,159,160,161],"Perioperative Cardiovascular Risk","myocardial injury","major adverse cardiac events","colchicine","2025-04-19",{"date":164,"type":38},"2025-04-24",{"date":166,"type":38},"2025-04-20",{"date":168,"type":21},"2029-03-30",{"name":44,"class":45},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":179,"conditions":180,"keywords":186,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":46},"100519392","microsurgical-resection-of-intramedullary-spinal-cord-metastases-100519392","NCT06042946","Microsurgical Resection of Intramedullary Spinal Cord Metastases","Microsurgical Resection of Intramedullary Spinal Cord Metastases - a Retrospective International Multicenter Study","Inclusion Criteria:\n\n* Adult patients admitted to one of the participating centres and treated for ISCM\n* Available documentation of admission and postoperative status\n\nExclusion Criteria:\n\n\\- Patients under the age of 18",{"count":178,"type":21},60,"The aim of the study is to establish a multi-center, retrospective database for patients with intramedullary spinal cord metastases (ISCM) and analyse the functional outcome in surgically treated ISCM patients.\n\nThe hypothesis is that the surgical treatment of selected ISCM patients does not lead to persistent morbidity and does not increase mortality, compared to patients that are treated non-operatively.\n\nSecondary objectives are to assess pre- to postoperative neurological deficits, ambulatory status, and overall survival of surgically treated ISCM patients.\n\nThe investigators intend to include a control cohort of patients with ISCM from participating centers, who underwent non-surgical oncological treatment (radiotherapy with or without chemotherapy). This control cohort of patients will be used to match patients with and without surgical treatment.\n\nPrimary endpoint (analysed in surgically treated ISCM patients):\n\nFunctional outcome at 90 days after treatment initiation, measured by the modified McCormick Scale. This is a score for grading of neurological function in spinal cord conditions.\n\nThe McCormick scale ranges from Grade I (neurologically intact) to grade V (paraplegic or quadriplegic). The McCormick scale is suitable for our retrospective study because of its good reproducibility and comparability.\n\nSecondary endpoints (analysed in surgically treated ISCM patients and analysed in matched patients with and without surgical treatment):\n\n* Functional outcome by the McCormick scale and the modified Japanese Orthopaedic Association scale (mJOA) at 6 and 12 months. This is a score evaluating motor function of upper and lower extremities, sensory function of upper extremities and sphincter function \u002F voidance. The mJOA ranges from 0 - 18 points, with higher score values representing better functional outcome. The minimum clinically important difference of the mJOA is 1-2 points, and scores lower than 14 indicate moderate myelopathy, scores lower than 11 indicate severe myelopathy.\n* Ambulatory status and continence at 90 days, 6 \\& 12 months (determined by mJOA subscores)\n* Neurological outcome, measured by American Spinal Cord Injury Association (ASIA)\n* Impairment Scale at 90 days, 6 and 12 months\n* Rate \\& type of complications at 90 days after treatment according to The Novel Therapy\n* Disability-Neurology Grade (TDN grade)16\n* Overall survival (in days)",[181,182,183,184,185],"Spinal Cord Metastasis","Spinal Cord Tumor Malignant Intramedullary","Functional Outcome","Radiotherapy; Complications","Spinal Cord Neoplasms",[187],"Spinal cord metastasis","2024-08-20",{"date":190,"type":38},"2024-08-21",{"date":192,"type":38},"2023-09-01",{"date":194,"type":21},"2025-07-31",{"name":44,"class":45},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":221,"locationsCount":46},"100517933","early-protected-full-weight-bearing-vs-partial-weight-bearing-after-surgical-fixation-of-unstable-ankle-fractures-monitored-with-bio-feedback-insoles-100517933","NCT06023979","Early Protected Full Weight-bearing vs. Partial Weight-bearing After Surgical Fixation of Unstable Ankle Fractures, Monitored With Bio-feedback Insoles.","Early Protected Full Weight-bearing vs. Partial Weight-bearing After Surgical Fixation of Unstable Ankle Fractures, Monitored With Bio-feedback Insoles. A Single Blinded Randomized Controlled Study","Inclusion Criteria:\n\n* patients with surgically stabilized unstable ankle fractures\n* signed informed consent\n* closed tibial and fibular epiphysis\n* age 18 or older\n\nExclusion Criteria:\n\n* dementia and other known cognitive impairment or incapacity of judgement\n* polytrauma\n* bilateral injury of the lower extremities\n* additional injury of the ipsilateral lower extremity which prevents full weight bearing\n* associated injury of one or both upper extremities\n* open fractures grade II° and III°\n* chronic loss of sensation on plantar aspect of the feet due to known distal neuropathy\n* open epiphysis\n* pregnancy",{"count":204,"type":21},110,[24],"The purpose of this study is to compare the postoperative results after ORIF (Open Reduction Inner Fixation) with a partial weight-bearing protocol versus an early full weight-bearing protocol. But in addition, we will measure every patient's actual load by the means of walker integrated bio-feedback insoles for the first six postoperative weeks to record the adherence to the protocol.",[208],"Post Operative Treatment After Unstable Malleolar Fractures",[210,211,212,213,214],"malleolar fractures","postoperative treatment protocol","full weight bearing","partial weight bearing","bio-feedback insoles","2023-08-29",{"date":217,"type":38},"2023-09-05",{"date":192,"type":21},{"date":220,"type":21},"2026-10-31",{"name":44,"class":45},""]